General Information
Age Group
AdultStatus
ActiveProtocol Number
NCT02554903Background Information
This trial seeks to evaluate the efficacy of Macitentan in patients with pulmonary hypertension after left-ventricular device (LVAD) implantation.
This study is a US-based, prospective, double-blind, multicenter, placebo-controlled, randomized 1:1, pulmonary hypertension in LVAD patients trial.
Offered At
Inova Heart and Vascular Institute
3300 Gallows Road
Falls Church, VA 22042
Principal Investigator
Shashank Desai, MD
Eligibility Information
- 18 years or older
- LVAD Implantation within last 45 days
- Evidence of pulmonary hypertension post-LVAD implantation via the following:
- mPAP ≥ 25mmHg
- PCWP ≤ 18mmHg
- PVR > 3 Wood Units
Ineligibility Information
- Hemoglobin < 8.5mg/dl
- GFR < 30
- FEV1 < 50% predicted
- Participating in another prospective LVAD study (e.g. HeartMate3)
Contact Name
Bhruga Shah
703-776-2995
bhruga.shah@inova.org
or
Vinita Gupta
703-776-3697
vinita.gupta@inova.org
or
Call the main Advanced Heart Failure Research office at 703-776-2828